Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 05:53 am IST
Share
Daewon Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 199.12 million compared to KRW 29.32 million a year ago. Net income was KRW 11,072.14 million compared to KRW 6,272.28 million a year ago. Basic earnings per share from continuing operations was KRW 522 compared to KRW 295.1456 a year ago. Diluted earnings per share from continuing operations was KRW 510. Basic earnings per share was KRW 522 compared to KRW 304 a year ago. Diluted earnings per share was KRW 510.
For the nine months, sales was KRW 421.54 million compared to KRW 58.66 million a year ago. Net income was KRW 28,979.21 million compared to KRW 1,240.08 million a year ago. Basic earnings per share from continuing operations was KRW 1,366 compared to KRW 58.2524 a year ago. Diluted earnings per share from continuing operations was KRW 1,334. Basic earnings per share was KRW 1,366 compared to KRW 60 a year ago. Diluted earnings per share was KRW 1,334.
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
DAEWON PHARMACEUTICAL CO., LTD. 
